CompletedNCT05113953
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating disorders
Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Phoenix and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 22, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 147
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05113953
- Official title
Show the full official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets After Oral Administration in Adult Subjects With Binge Eating Disorder
Get this study by email
Recruitment & locations
CompletedPhoenix · Beverly Hills · Encino
21 more locations
- Garden Grove
- Upland
- Denver
- Jacksonville
- Miami
- Decatur
- Marietta
- Overland Park
- Prairie Village
- Boston
- Weldon Spring
- Portsmouth
- Cherry Hill
- Princeton
- New York
- Staten Island
- Dayton
- Mason
- Memphis
- Austin
- Dallas
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Centanafadine and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
